|Bid||156.32 x 800|
|Ask||156.31 x 800|
|Day's range||154.09 - 156.69|
|52-week range||150.11 - 183.35|
|Beta (5Y monthly)||0.53|
|PE ratio (TTM)||32.73|
|Earnings date||20 Jul 2023|
|Forward dividend & yield||4.76 (3.07%)|
|Ex-dividend date||22 May 2023|
|1y target est||179.71|
Many high-quality dividend stocks currently yield around 3%, nearly double that of the S&P 500. American Tower's dividend yield is currently over 3%, a historically high rate for the data-infrastructure real estate investment trust (REIT). The company has an exceptional track record of paying dividends.
A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs' misuse of confidential records they obtained through related litigation. The lawsuit, which accused J&J's DePuy Orthopaedics unit of defrauding the federal government by marketing defective hip implants, was dismissed in December 2021. J&J has denied wrongdoing.
It could take years before Nano-X proves there's strong demand for its devices, and even longer to reach profitability.
The Dow Jones Industrial Average consists of 30 of the most established businesses in the world. Thus, it shouldn't be a surprise to learn that many of the components that belong to this index have decades of dividend growth to their credit. Here are two Dow Jones stocks with more than a century of dividend growth between them to consider buying this month.
Adding these well-respected dividend payers to your portfolio could give you a stream of passive income that grows throughout your retirement years.
Based on a 58-year track record as CEO of Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B), it's safe to say Warren Buffett knows a thing or two about investing. As of this past weekend, he'd overseen a greater than 3,900,000% return in his company's Class A shares (BRK.A) since taking the reins at Berkshire. What follows are three Warren Buffett stocks that stand out as screaming buys in June.
Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.
(Bloomberg) -- Eli Lilly & Co.’s third straight month of gains has helped it become the largest pharmaceutical company in the world by market value, surpassing Johnson & Johnson.
(Reuters) -Johnson & Johnson on Wednesday faced the first trial in almost two years over claims that asbestos in its baby powder and other talc products causes cancer, as it seeks to settle thousands of similar cases in bankruptcy court. Emory Hernandez, 24, says he developed mesothelioma, a deadly cancer, in the tissue around his heart as a result of exposure to J&J's talc products beginning when he was a baby.
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.
In the latest trading session, Johnson & Johnson (JNJ) closed at $154.37, marking a +0.01% move from the previous day.
InMode, Johnson & Johnson, Intuitive Surgical and GE HealthCare are included in this Analyst Blog.
Not all dividend stocks are created equal. Some appear to be much more secure than others. Here are two I'd say fit into that category. The post 2 of the safest dividend stocks on Earth appeared first on The Motley Fool UK.
Warren Buffett loves dividend stocks. With passive income on my mind, I'm looking at Berkshire Hathaway's portfolio for inspiration. The post I’d invest £10k in these 2 Warren Buffett stocks for £365 in passive income a year appeared first on The Motley Fool UK.
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
If you're like Warren Buffett, you favor solid companies that perform over the long term -- and, at the same time, reward investors with passive income. Buffett has made his fortune -- and the fortune of others as Berkshire Hathaway chairman -- by sticking to that idea. Well, an opportunity is here for two Buffett favorites.
(Bloomberg) -- Kenvue Inc., the consumer health business that Johnson & Johnson spun off this month, will be eligible for ratings from a slew of major Wall Street banks next week, offering a chance to see how analysts are assessing initial public offerings amid the latest equities volatility and recession worries. Most Read from BloombergBiden, McCarthy Forge Debt Deal in Bid to Avert US DefaultWorld’s Richest Man Throws In Towel on Beverly Hills HotelKey Takeaways From Deal Biden, GOP Sealed to
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
Many investors actively seek dividend stocks, and who can blame them? Choosing the right dividend stocks is arguably the best way to avoid this risk: Not all dividend stocks are created equal. With that said, let's turn our attention to two companies that are practically passive income machines and will likely continue rewarding shareholders with payout increases for a long time: Johnson & Johnson (NYSE: JNJ) and Apple (NASDAQ: AAPL).
CNBC's Jim Cramer predicts a booming bull market for medical devices, with positive earnings reports across the space. INMD, JNJ, ISRG and GEHC can emerge as potential winners.
When you think of Johnson & Johnson (NYSE: JNJ), you may think of shampoo and Band-Aids. In fact, J&J is in the process of spinning off that business into an entity called Kenvue. What is J&J's top revenue driver?
Key Insights The projected fair value for Johnson & Johnson is US$202 based on 2 Stage Free Cash Flow to Equity Johnson...
Johnson & Johnson (JNJ) closed the most recent trading day at $156.66, moving -0.1% from the previous trading session.